Targeting CD8⁺ T cells prevents psoriasis development - 01/07/16

Doi : 10.1016/j.jaci.2015.10.046

Paola Di Meglio, PhD ^a,^{^{∗
These authors contributed equally to this work.},}^{^{‡
Paola Di Meglio is currently at The Francis Crick Institute, Mill Hill Laboratory, London, United Kingdom.}}, Federica Villanova, PhD ^a,^b,^{^{∗
These authors contributed equally to this work.}}, Alexander A. Navarini, MD, PhD ^c,^{^{∗
These authors contributed equally to this work.}}, Alessio Mylonas, MSc ^d, Isabella Tosi, MSc ^a,^b, Frank O. Nestle, MD ^a,^b, Curdin Conrad, MD ^d
^a St John's Institute of Dermatology, King's College London, London, United Kingdom
^b NIHR Biomedical Research Centre, King's College London, London, United Kingdom
^c Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
^d Department of Dermatology, University Hospital of Lausanne CHUV, Lausanne, Switzerland

C.C. was supported by grant funding from the Faculty of Biology and Medicine of the University of Lausanne. The research was in part funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' National Health Service (NHS) Foundation Trust and King's College London (to F.O.N.). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, or other funding bodies.

Disclosure of potential conflict of interest: P. Di Meglio has received grants from the National Institute for Health Research (NIHR) Biomedical Research Centre and Celgene and has received payment for the development of educational presentations from Jansenn. F. Villanova and I. Tosi have received grants from the NIHR Biomedical Research Centre. A. A. Navarini has consultant arrangements with AbbVie and Celgene and has received payment for lectures from AbbVie, Celgene, Pfizer, and Novartis. A. Mylonas has received a grant from the Faculty of Biology and Medicine of the University of Lausanne. F. O. Nestle has received a grant from the NIHR Biomedical Research Centre and has consultant arrangements with AbbVie, Amgen, Boehringer Ingelheim, Celgene, GSK, Janssen, Eli Lilly, Novartis, Pfizer, and Sanofi. C. Conrad has received a grant from the Faculty of Biology and Medicine of the University of Lausanne; has consultant arrangements with AbbVie, Actelion, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, MSD, Novartis, and Pfizer; and has received payment for lectures from AbbVie, Celgene, Janssen-Cilag, Leo Pharma, MSD, Novartis, and Pfizer.

Export

Vol 138 - N° 1

P. 274 - juillet 2016 Retour au numéro

Article précédent

Epicutaneous immunization with ovalbumin and CpG induces T_H1/T_H17 cytokines, which regulate IgE and IgG_2a production
Monika Majewska-Szczepanik, Philip W. Askenase, Francis M. Lobo, Katarzyna Marci?ska, Li Wen, Marian Szczepanik

| Article suivant

Human nasal epithelial cells derived from multiple subjects exhibit differential responses to H3N2 influenza virus infection in vitro
Yan Yan, Kai Sen Tan, Chunwei Li, Thai Tran, Siew Shuen Chao, Richard J. Sugrue, Li Shi, Vincent T. Chow, De-Yun Wang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Targeting CD8⁺ T cells prevents psoriasis development - 01/07/16

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL